A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : FLCs / free light chains

[Related PubMed/MEDLINE]
Total Number of Papers: 91
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   FLCs  (>> Co-occurring Abbreviation)
Long Form:   free light chains
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 B cell homeostasis is maintained during long-duration spaceflight. ISS
2019 Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report. AKI, MCN, MM
2019 Free light chains and autoimmunity. ---
2019 Idiotype-specific intravenous immunoglobulin for therapy of immunoglobulin kappa free light chain deficiency. CVID, IVIG
2018 B-cell activity markers are associated with different disease activity domains in primary Sjogren's syndrome. beta 2m, ESSDAI, pSS, UKPSSR
2018 Intensified training increases salivary free light chains in trained cyclists: Indication that training volume increases oral inflammation. IT, TT
2018 Serological profile of asymptomatic HCV positive patients with low level of cryoglobulins. CGs, HCV, MC, RF
2018 Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjogren's syndrome. ESSDAI, MALT, pSS
2017 A novel approach for the chromatographic purification and peptide mass fingerprinting of urinary free light chains. kappa-FLCs, lamda-FLCs, MS
10  2017 Characteristics of Vitamin B12 Deficiency in Patients With Plasma Cell Disorders. PCDs
11  2017 Diagnostic accuracy of salivary and serum-free light chain assays in primary Sjogren's syndrome: a pilot study. pSS
12  2017 KFLC Index utility in multiple sclerosis diagnosis: Further confirmation. MS
13  2017 Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. dFLC, OS, RS
14  2017 The role of free kappa and lambda light chains in the pathogenesis and treatment of inflammatory diseases. IBD, PTCs
15  2017 Urinary free light chains may help to identify infection in patients with elevated systemic inflammation due to rheumatic disease. ---
16  2016 Citrate Extended High Cut-Off Hemodiafiltration for Renal Recovery in Patients With Multiple Myeloma. HCO
17  2016 Comparison of Free Light Chain Assays:  Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis. ---
18  2016 Follow-up of IgD-kappa multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report. Ig, MM
19  2016 Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD. A1ATD, COPD
20  2016 Peripheral blood neutrophil extracellular trap production and degradation in chronic periodontitis. IgG, NET, PBN
21  2016 Salivary immunoglobulin free light chains: reference ranges and responses to exercise in young and older adults. TT
22  2016 Serum free light chains are reduced in endurance trained older adults: Evidence that exercise training may reduce basal inflammation in older adults. ---
23  2016 The significance and predictive value of free light chains in the urine of patients with chronic inflammatory rheumatic disease. ---
24  2015 A subset of AID-dependent B-1a cells initiates hypersensitivity and pneumococcal pneumonia resistance. Ab, AID, cB-1a, CS, DTH, sB-1a cells
25  2015 Aggressive FLC Escape in a Patient with IgD Myeloma. ---
26  2015 Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies. EBV, SLE, SLEDAI
27  2015 Exploring the Relationship Between Serum and Urinary Free Light Chain Levels During the Different Phases of Renal Damage in Multiple Myeloma Patients. MM, sFLCs, uFLCs
28  2015 Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. BTK, CLL, FDA, IgG
29  2015 Plasmapheresis in cast nephropathy: yes or no? ---
30  2015 Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies. FLC
31  2014 Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy. IFE, MG
32  2014 Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjogren's syndrome? Abs, pSS
33  2014 Immunoglobulin Free Light Chains and GAGs Mediate Multiple Myeloma Extracellular Vesicles Uptake and Secondary NfkappaB Nuclear Translocation. EVs, MGUS, MM
34  2014 Serum free light chains in clinical laboratory diagnostics. sFLC
35  2014 Treatment of acute kidney injury with cast nephropathy. AKI, HCO-HD, THP, TPE
36  2014 [Amyloid light chain amyloidosis]. AL
37  2013 Association between free light chain levels, and disease progression and mortality in chronic kidney disease. CKD
38  2013 Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma. CI, DLBCL, GELA, HLC, HR, Ig, IPI, OS, PFS, R-CHOP
39  2013 Plasma markers of B-cell activation and clonality in pediatric liver and hematopoietic stem cell transplant recipients. EBV, PTLD, sCD30
40  2013 Urinary free light chain is a potential biomarker for ISN/RPS class III/IV lupus nephritis. ISN/RPS
41  2012 Circulating antibody free light chains and risk of posttransplant lymphoproliferative disorder. EBV, OR, PTLD
42  2012 Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals. CI, HIV, ORs
43  2012 Immunobiology of antigen-specific immunoglobulin free light chains in chronic inflammatory diseases. ---
44  2012 Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. CDR3, THP
45  2012 Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. MM
46  2012 New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. dFLC
47  2012 Novel approaches for reducing free light chains in patients with myeloma kidney. ---
48  2012 Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis. ASK1
49  2012 Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. HIV, HL, NHL, sFLC, UNL
50  2012 The pathogenesis of acute kidney impairment in patients with multiple myeloma. ---
51  2012 The role of immunological assessment in patients with acute kidney injury and possible myeloma. AKI, MM
52  2012 Treating myeloma cast nephropathy without treating myeloma. THP
53  2011 Comparison of free light chain removal by four blood purification methods. HCO
54  2011 Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. ---
55  2011 Immunoglobulin free light chains are increased in hypersensitivity pneumonitis and idiopathic pulmonary fibrosis. HP, IPF
56  2011 Immunoglobulin light chains activate nuclear factor-kappaB in renal epithelial cells through a Src-dependent mechanism. IkappaB, IKKs, MCP-1, NF-kappaB
57  2011 Influence of immunoglobulin light chain dimers on the results of the quantitative nephelometric assay. AL, MM, SDS-PAGE
58  2011 Interlaboratory study of free monoclonal immunoglobulin light chain quantification. ---
59  2011 Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. CI, CLL, HR
60  2011 The biology of immunoglobulin free light chains and kidney injury. ---
61  2010 Analytical performance of the serum free light chain assay. ---
62  2010 Chronic lymphocytic leukemia with associated lambda-light-chain and IgG lambda paraproteins simulating a biclonal gammopathy. CLL, MCs
63  2010 Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. ACPA, ESR, Ig, RA, RF, SF
64  2010 Detection of serum free light chains: the problem with antigen excess. ---
65  2010 Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis. NARES
66  2010 Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. AL, OS
67  2010 [Clinical significance of measurement of free light chains]. ---
68  2009 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. EM, Ig, LCE, MM, SFLCs
69  2009 Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. CLL
70  2009 Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. AL, NALCDD
71  2009 Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. MGUS, MM, PLCO
72  2009 Serum free light chain assessment in monoclonal gammopathy and kidney disease. ---
73  2009 Serum free light chains: diagnostic and prognostic value in multiple myeloma. MM, PE
74  2008 European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. ---
75  2008 Immunoglobulin free light chains: do they have a role in plasma cell leukemia? PCL
76  2008 Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis. ---
77  2008 Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease? ACRs
78  2008 Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. SPE
79  2008 Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. HD
80  2007 Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. pSS, SE
81  2006 Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. AL
82  2006 Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. BJP, SPEP
83  2006 Systemic immunoglobulin light-chain amyloidosis. SCT
84  2006 [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma]. ---
85  2005 Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. AL, IFE, LCDD, NSMM, PCDs
86  2005 Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. ---
87  2004 Free light-chain proteinuria and normal renal histopathology and function in 11 dogs exposed to Lleishmania infantum, Ehrlichia canis, and Bbabesia canis. SDS-AGE
88  2002 Influence of plasma immunoglobulin level on antibody synthesis. IA, IgG
89  2002 Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. ---
90  2002 Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. ---
91  2001 Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. ---